KLK6 mediates stemness and metabolism of gastric carcinoma cells via the PI3K/AKT/mTOR signaling pathway

Zhou,Dong; He,Yanping; Li,Hengping; Huang,Weidong

doi:10.3892/ol.2021.13085

KLK6 mediates stemness and metabolism of gastric carcinoma cells via the PI3K/AKT/mTOR signaling pathway

Authors:
- Dong Zhou
- Yanping He
- Hengping Li
- Weidong Huang
View Affiliations

Affiliations: Department of Vascular Surgery, First People's Hospital of Xiangyang City, Hubei Medical College, Xiangyang, Hubei 441000, P.R. China
Published online on: October 12, 2021 https://doi.org/10.3892/ol.2021.13085
Article Number: 824

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is a common tumor of the digestive system, which can occur in any part of the stomach. Kallikrein 6 (KLK6) is a trypsin‑like serine protease and has been found to be involved in extracellular matrix remodeling, tumor invasion and nervous system plasticity. Our previous study reported that KLK6 suppressed HGC‑27 gastric cancer cell growth by inhibiting epithelial‑mesenchymal transition; however, the mechanism of action underlying the effect of KLK6 still remains unclear. The aim of the present study was to investigate the effect and the underlying mechanism of KLK6 on stem cell‑like properties and metabolism in gastric carcinoma cells. The HGC‑27 cell line was transfected with KLK6 overexpression (OV‑KLK6) and interference (short hairpin‑KLK6) vectors, then the transfection efficiency was confirmed using western blot analysis and reverse transcription‑quantitative PCR. The percentage of CD133⁺ and CD44⁺ cells was detected using flow cytometry, while the protein expression levels of the stem‑associated genes, Nanog, Oct‑4, SOX2 and Notch1, the metabolic markers, hexokinase (HK)1, HK2, GLUT1, and the proteins within the PI3K signaling pathway, phosphorylated (p)‑PI3K, p‑AKT and p‑mTOR, were determined using western blot analysis. Biochemical kits were used to measure ATP production, lactic acid content and glucose uptake. A tumorigenicity assay was performed with nude mice to detect gastric tumor volume, and the protein expression level of Oct‑4, Nanog, HK1, HK2 and GLUT1, and the mRNA expression level of KLK6 was also determined in gastric tumor tissues of mice. Compared with that in the control group, KLK6 protein and mRNA expression levels were significantly decreased in the four sh‑RNA groups (P<0.05). Among them, sh‑RNA‑3 induced the lowest KLK6 expression and was used to silence KLK6 in subsequent experiments. Compared with that in the control and negative control groups, the percentage of CD133⁺ and CD44⁺ cells, the protein expression level of Oct‑4, Nanog, HK1, HK2, GLUT1, p‑PI3K, p‑AKT and p‑mTOR, and ATP content, lactic acid production, glucose uptake and gastric tumor volume were significantly decreased by sh‑KLK6 (P<0.05), whereas KLK6 overexpression induced the opposite effect (P<0.05). In conclusion, KLK6 modulated stemness properties and cell metabolic profile in gastric carcinoma cells and the mechanism may be associated with the PI3K/AKT/mTOR signaling pathway.

View Figures

View References

1	Yada T, Yokoi C and Uemura N: The current state of diagnosis and treatment for early gastric cancer. Diagn Ther Endosc. 2013:2413202013. View Article : Google Scholar
2	Li YX, Li XM, Zhang L, Zhang W, Chen C, Tao L, Zhao J, Li SG, Li F and Zhang WJ: Correlation between Helicobacter pylori infection and the development and prognosis of gastric cancer. Chin J Can Prev Trea. 2:19-22+36. 2015.(In Chinese).
3	Zuo TT, Zheng SR, Zeng HM, Zhang SW and Chen WQ: Epidemiological status of gastric cancer in China. Chin Cancer Clin l. 442017.
4	Cai M, Dai S, Chen W, Xia C, Lu L, Dai S, Qi J, Wang M, Wang M, Zhou L, et al: Environmental factors, seven GWAS-identified susceptibility loci, and risk of gastric cancer and its precursors in a Chinese population. Cancer Med. 6:708–720. 2017. View Article : Google Scholar
5	Karimi P, Islami F, Anandasabapathy S, Freedman ND and Kamangar F: Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar
6	Song Z, Wu Y, Yang J, Yang D and Fang X: Progress in the treatment of advanced gastric cancer. Tumour Biol. 39:10104283177146262017. View Article : Google Scholar
7	Smyth EC, Nilsson M, Grabsch HI, van Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648. 2020. View Article : Google Scholar
8	Wang ZD, Yang J and Guo QW: Tumor stem cells-a new target for tumor therapy. J Clin Exp Pathol. 29:427–430. 2013.
9	Vinogradov S and Wei X: Cancer stem cells and drug resistance: The potential of nanomedicine. Nanomedicine (Lond). 7:597–615. 2012. View Article : Google Scholar
10	Gopalan V, Islam F and Lam KY: Surface markers for the identification of cancer stem cells. Methods Mol Biol. 1692:17–29. 2018. View Article : Google Scholar
11	Kapeleris J, Zou H, Qi Y, Gu YS, Li J, Schoning J, Monteiro MJ and Gu W: Cancer stemness contributes to cluster formation of colon cancer cells and high metastatic potentials. Clin Exp Pharmacol Physiol. 47:838–847. 2020. View Article : Google Scholar
12	de Sousa e Melo F, Kurtova AV, Harnoss JM, Kljavin N, Hoeck JD, Hung J, Anderson JE, Storm EE, Modrusan Z, Koeppen H, et al: A distinct role for Lgr5⁺ stem cells in primary and metastatic colon cancer. Nature. 543:676–680. 2017. View Article : Google Scholar
13	Liu H, Chen K, Wang L, Zeng X, Huang Z, Li M, Dong P and Chen X: miR-613 inhibits Warburg effect in gastric cancer by targeting PFKFB2. Biochem Biophys Res Commun. 515:37–43. 2019. View Article : Google Scholar
14	Qin XY, Xu HY and Lai LH: Targeting tumor metabolic pathways to develop anticancer agents. 12th national congress of Chinese society of biochemistry and molecular biology and 2018 national academic conference. 2018.
15	Nagahara H, Mimori K, Utsunomiya T, Barnard GF, Ohira M, Hirakawa K and Mori M: Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Can Res. 11:6800–6806. 2005. View Article : Google Scholar
16	Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F and Adam A: The kallikrein-kinin system: Current and future pharmacological targets. J Pharmacol Sci. 99:6–38. 2005. View Article : Google Scholar
17	Schrader CH, Kolb M, Zaoui K, Flechtenmacher C, Grabe N, Weber KJ, Hielscher T, Plinkert PK and Hess J: Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients. Mol Cancer. 14:1072015. View Article : Google Scholar
18	Sells E, Pandey R, Chen H, Skovan BA, Cui HY and Ignatenko NA: Specific microRNA-mRNA regulatory network of colon cancer invasion mediated by tissue kallikrein-related peptidase 6. Neoplasia. 19:396–411. 2017. View Article : Google Scholar
19	Kaneko N, Kawano S, Yasuda K, Hashiguchi Y, Sakamoto T, Matsubara R, Goto Y, Jinno T, Maruse Y, Morioka M, et al: Differential roles of kallikrein-related peptidase 6 in malignant transformation and ΔNp63β-mediated epithelial-mesenchymal transition of oral squamous cell carcinoma. Oral Oncol. 75:148–157. 2017. View Article : Google Scholar
20	Plaks V, Kong N and Werb Z: The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 16:225–238. 2015. View Article : Google Scholar
21	Pastushenko I, Mauri F, Song Y, de Cock F, Meeusen B, Swedlund B, Impens F, Van Haver D, Opitz M, Thery M, et al: Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature. 589:448–455. 2021. View Article : Google Scholar
22	Pattabiraman DR and Weinberg RA: Tackling the cancer stem cells-what challenges do they pose? Nat Rev Dr Dis. 13:497–512. 2014. View Article : Google Scholar
23	Lytle NK, Barber AG and Reya T: Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 18:669–680. 2018. View Article : Google Scholar
24	Shorning BY, Dass MS, Smalley MJ and Pearson HB: The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 21:45072020. View Article : Google Scholar
25	Porta C, Paglino C and Mosca A: Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014. View Article : Google Scholar
26	Fattahi S, Amjadi-Moheb F, Tabaripour R, Ashrafi GH and Akhavan-Niaki H: PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond. Life Sci. 262:1185132020. View Article : Google Scholar
27	Wang C, Xie J, Guo J, Manning HC, Gore JC and Guo N: Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep. 28:1301–1308. 2012. View Article : Google Scholar
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
29	Jin JF, Ou XB, Ruan Y and Guo RZ: Establishment of a xenograft model in nude mice with human gastric cancer HGC-27 cells. J Zunyi Med Coll. 1:33–35. 2015.
30	Rao M, Zhu Y, Cong X and Li Q: Knockdown of CREB1 inhibits tumor growth of human gastric cancer in vitro and in vivo. Oncol Rep. 37:3361–3368. 2017. View Article : Google Scholar
31	Fagoonee S, Li H, Zhang H, Altruda F and Pellicano R: Gastric cancer as a stem-cell disease: Data and hypotheses. Panminerva Med. 56:289–300. 2014.
32	Hata M, Hayakawa Y and Koike K: Gastric stem cell and cellular origin of cancer. Biomedicines. 6:1002018. View Article : Google Scholar
33	Moharil RB, Dive A, Khandekar S and Bodhade A: Cancer stem cells: An insight. J Oral Maxillofac Pathol. 21:4632017. View Article : Google Scholar
34	Dawood S, Austin L and Cristofanilli M: Cancer stem cells: Implications for cancer therapy. Oncology (Williston Park). 28:1101–1107, 1110. 2014.
35	Yang LX, Qin SJ and Dong MQ: Advances in anti-tumor strategies based on targeted tumor stem cells. Shandong Med. 59:91–94. 2019.
36	Gao GL, Zhang XL, Sun ZL, Liu WY, Zhang P and Ye DX: Isolation and identification cancer stem cells in human gastric cancer cell line 7. Shanghai Med. 37:957-961+897. 2014.(In Chinese).
37	Maiuthed A, Chantarawong W and Chanvorachote P: Lung cancer stem cells and cancer stem cell-targeting natural compounds. Anticancer Res. 38:3797–3809. 2018. View Article : Google Scholar
38	Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL and Rich JN: Cancer stem cells in glioblastoma. Genes Dev. 29:1203–1217. 2015. View Article : Google Scholar
39	Troschel FM, Böhly N, Borrmann K, Braun T, Schwickert A, Kiesel L, Eich HT, Götte M and Greve B: miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro. Tumour Biol. 40:10104283187918872018. View Article : Google Scholar
40	Giraud J, Molina-Castro S, Seeneevassen L, Sifré E, Izotte J, Tiffon C, Staedel C, Boeuf H, Fernandez S, Barthelemy P, et al: Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells. Int J Cancer. 146:2255–2267. 2020. View Article : Google Scholar
41	Ni T, Wang H, Zhan D, Tao L, Lv M, Wang W, Chu Z, Zhou Z, Sunagawa M and Liu Y: CD133+/CD166+ human gastric adenocarcinoma cells present the properties of neoplastic stem cells and emerge more malignant features. Life Sci. 269:1190212021. View Article : Google Scholar
42	Shariati F, Favaedi R, Ramazanali F, Ghoraeian P, Afsharian P, Aflatoonian B, Aflatoonian R and Shahhoseini M: Increased expression of stemness genes REX-1, OCT-4, NANOG, and SOX-2 in women with ovarian endometriosis versus normal endometrium: A case-control study. Int J Reprod Biomed. 16:ijrm.v16i12.3684. 2019.
43	Khosravi A, Jafari SM and Asadi J: Knockdown of TAZ decrease the cancer stem properties of ESCC cell line YM-1 by modulation of Nanog, OCT-4 and SOX2. Gene. 769:1452072021. View Article : Google Scholar
44	Yan JW, Zhong J, Wang GC and Feng F: Progress in research of targeting cancer glycolysis pathway for anticancer therapy. Chin J New Drugs. 23:550–556. 2014.
45	Zuo RJ: Warburg effect: Aerobic glycolysis during mammalian reproduction. Prog Biochemis Biophy. 42:132–139. 2015.
46	Wang YZ, Liu BL and Li XY: Progress in the study of glucose transporter 1 at the blood-brain barrier. Chin J Clin Pharm Ther. 19:1057–1063. 2014.
47	Chen R, Lin J, Yan W and Chen D: miR-522-3p promotes osteosarcoma cell growth by regulating glucose uptake and GLUT1 expression. Onco Targets Ther. 12:9053–9058. 2019. View Article : Google Scholar
48	Lis P, Dyląg M, Niedźwiecka K, Ko YH, Pedersen PL, Goffeau A and Ułaszewski S: The HK2 dependent ‘Warburg effect’ and mitochondrial oxidative phosphorylation in cancer: Targets for effective therapy with 3-bromopyruvate. Molecules. 21:17302016. View Article : Google Scholar
49	Xia HG, Najafov A, Geng J, Galan-Acosta L, Han X, Guo Y, Shan B, Zhang Y, Norberg E, Zhang T, et al: Degradation of HK2 by chaperone-mediated autophagy promotes metabolic catastrophe and cell death. J Cell Biol. 210:705–716. 2015. View Article : Google Scholar